histogen
announces
completion
final
dosing
timepoint
milestone
trial
androgenic
alopecia
men
san
diego
globe
newswire
histogen
nasdaq
hsto
therapeutics
company
focused
developing
potential
restorative
therapeutics
ignite
body
natural
process
repair
maintain
healthy
biological
function
today
announced
completion
patient
dosing
phase
clinical
trial
designed
assess
safety
tolerability
indicators
efficacy
treatment
androgenic
alopecia
men
pleased
completed
dosing
week
last
three
dosing
timepoints
trial
remain
track
announce
top
line
data
results
fourth
quarter
year
said
richard
pascoe
histogen
president
ceo
believe
potential
stimulate
new
hair
growth
contrast
two
fda
approved
therapies
focus
reducing
hair
phase
trial
blinded
randomized
placebo
controlled
single
site
study
enrolled
subjects
male
pattern
hair
loss
using
randomization
placebo
designed
assess
safety
tolerability
well
indicators
efficacy
including
hair
count
total
hair
count
hair
thickness
density
measured
canfield
macrophotography
treatment
timepoint
weeks
subjects
receive
total
injections
vertex
scalp
region
temporal
recession
region
common
areas
hair
loss
men
androgenic
alopecia
primary
secondary
endpoints
assessed
week
data
anticipated
available
fourth
quarter
hair
stimulating
complex
hsc
intended
therapeutic
hair
loss
hsc
anticipated
relatively
safe
minimally
invasive
treatment
promotes
new
hair
growth
existing
treatments
reduce
hair
loss
hsc
manufactured
enrich
growth
factors
including
kgf
vegf
follistatin
involved
signaling
stem
cells
body
shown
important
hair
formation
stimulation
resting
hair
follicles
histogen
histogen
therapeutics
company
focused
developing
potential
restorative
therapeutics
ignite
body
natural
process
repair
maintain
healthy
biological
function
histogen
innovative
technology
platform
utilizes
cell
conditioned
media
extracellular
matrix
materials
produced
multipotent
cells
histogen
proprietary
reproducible
manufacturing
process
provides
targeted
solutions
across
broad
range
therapeutic
indications
including
hair
growth
dermal
rejuvenation
joint
cartilage
regeneration
spinal
disk
repair
information
please
visit
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
example
using
statements
discuss
future
operations
ability
successfully
initiate
complete
clinical
trials
obtain
clinical
trial
data
achieve
regulatory
milestones
related
timing
including
related
reporting
topline
data
ongoing
phase
clinical
trial
treatment
androgenic
alopecia
men
nature
strategy
focus
business
sufficiency
cash
resources
ability
achieve
value
stockholders
development
commercial
potential
potential
benefits
product
candidates
including
may
actually
achieve
plans
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
statements
deal
future
events
based
current
expectations
subject
various
risks
uncertainties
actual
results
performance
achievements
could
differ
materially
described
implied
statements
press
release
including
uncertainties
associated
clinical
development
regulatory
approval
product
candidates
including
potential
delays
commencement
enrollment
completion
clinical
trials
reporting
topline
data
ongoing
phase
clinical
trial
treatment
androgenic
alopecia
men
potential
earlier
clinical
trials
studies
histogen
product
candidates
may
predictive
future
results
risks
related
business
interruptions
including
outbreak
coronavirus
could
seriously
harm
financial
condition
increase
costs
expenses
requirement
additional
capital
continue
advance
product
candidates
may
available
favorable
terms
foregoing
review
important
factors
could
cause
actual
events
differ
expectations
construed
exhaustive
read
conjunction
statements
included
herein
elsewhere
including
risks
discussed
filings
securities
exchange
commission
except
otherwise
required
law
disclaim
intention
obligation
update
revise
statements
speak
date
hereof
whether
result
new
information
future
events
circumstances
otherwise
contact
susan
knudson
executive
vice
president
cfo
histogen
ir
